SG3 Management’s Ascendis Pharma A/S ASND Stock Holding History

SG3 Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-21,600	Closed	-$2.54M	–	430
2022 Q1	$2.54M	Buy	+21,600	New	+$2.5M	0.07%	255
2021 Q3	–	Sell	-5,000	Closed	-$658K	–	982
2021 Q2	$658K	Sell	5,000 -5,000	-50%	-$666K	0.02%	591
2021 Q1	$1.29M	Buy	+10,000	New	+$1.52M	0.03%	530

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SG3 Management's ASND Position: Q1 2023 in Review

SG3 Management sold out of Ascendis Pharma A/S (ASND) in Q1 2023, closing a stake of 2,000 shares — an estimated $244K sold.

SG3 Management first reported a position in ASND in Q2 2021 and held it in 3 quarters. The position peaked at $526K in Q2 2021. 164 funds tracked by Wall St. Rank hold ASND as of Q1 2023.

SG3 Management reported no remaining Ascendis Pharma A/S position as of Q1 2023 after selling out during the quarter.
SG3 Management sold 2,000 Ascendis Pharma A/S shares in Q1 2023, an estimated $244K.
SG3 Management first reported a position in Ascendis Pharma A/S in Q2 2021 and held it in 3 quarters.
SG3 Management's Ascendis Pharma A/S position peaked at $526K in Q2 2021.
164 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.